4 months ago
LLY
AnalystsEvan SeigermanEvan Seigerman's Stock Forecasts
AnalystsEvan Seigerman
Analyst Ranking
Bottom 16%
#3765 out of 4426 analysts
Average Return
-2.07%
Win Rate
37%22 out of 59
Risk vs Reward
Poor
Good
Evan Seigerman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Disc Medicine IncIRON | +167.12% | $22.84 | $61.01 | 2023-03-23 - 2023-12-08 | Buy |
Structure Therapeutics IncGPCR | +142.06% | $25.56 | $61.87 | 2023-02-28 - 2023-12-08 | Buy |
Eli Lilly & CoLLY | +39.59% | $428.44 | $598.05 | 2023-05-04 - 2023-12-08 | Buy |
Eli Lilly & CoLLY | +38.73% | $260.70 | $361.67 | 2021-11-19 - 2022-11-18 | Buy |
Eli Lilly & CoLLY | +35.51% | $292.13 | $395.86 | 2022-04-29 - 2023-04-28 | Buy |
Evan Seigerman Analyst Color
Get additional color on Evan Seigerman's coverage of popular stocks
7 months ago
LLY
2 years ago
PFE
Evan Seigerman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Neurocrine Biosciences IncNBIX | 7 | Hold | $100.00 | -14.73% | Maintains | a month ago |
Biogen IncBIIB | 10 | Buy | $295.00 | +23.28% | Maintains | a month ago |
Vertex Pharmaceuticals IncVRTX | 10 | Buy | $415.00 | +18.52% | Maintains | a month ago |
Bristol Myers Squibb CoBMY | 6 | Hold | $60.00 | +19.26% | Downgrades | a month ago |
Eli Lilly & CoLLY | 4 | Buy | $633.00 | +5.84% | Maintains | 4 months ago |
Incyte CorpINCY | 4 | Hold | $68.00 | +24.31% | Maintains | 4 months ago |
Disc Medicine IncIRON | 2 | Buy | $70.00 | +14.74% | Maintains | 6 months ago |
Gilead Sciences IncGILD | 8 | Buy | $100.00 | +26.55% | Upgrades | 7 months ago |
Structure Therapeutics IncGPCR | 1 | Buy | $40.00 | -35.35% | Initiates Coverage On | 9 months ago |
Mirati Therapeutics IncMRTX | 4 | Hold | $59.00 | N/A | Downgrades | a year ago |
Replimune Group IncREPL | 1 | Buy | $40.00 | N/A | Maintains | a year ago |
Regeneron Pharmaceuticals IncREGN | 9 | Buy | $788.00 | N/A | Maintains | a year ago |
Nuvation Bio IncNUVB | 2 | Hold | $2.50 | N/A | Downgrades | a year ago |
Candel Therapeutics IncCADL | 2 | Buy | $12.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 1 | Buy | $60.00 | N/A | Initiates Coverage On | 2 years ago |
Amgen IncAMGN | 4 | Hold | $228.00 | N/A | Initiates Coverage On | 2 years ago |
Ikena Oncology IncIKNA | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 3 years ago |
Satsuma Pharmaceuticals IncSTSA | 2 | Hold | $6.50 | N/A | Upgrades | 3 years ago |
Galera Therapeutics IncGRTX | 2 | Buy | $15.00 | N/A | Upgrades | 3 years ago |
Aimmune Therapeutics IncAIMT | 3 | Hold | $34.50 | N/A | Maintains | 3 years ago |
Acelrx Pharmaceuticals IncACRX | 5 | Sell | $16.80 | N/A | Maintains | 3 years ago |
Macrogenics IncMGNX | 1 | Buy | $13.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.